Division of Cancer Prevention

TMIST PI Pisano: “Are we further reducing breast cancer mortality the more intensively we screen?”

The Tomosynthesis Mammographic Imaging Screening Trial, a massive randomized trial of early detection, is asking an important question:  Is digital breast tomosynthesis better than digital mammography in reducing development of advanced breast cancer?

“We’ve done a really good job of getting women in to get screened, and that’s good because we are undoubtedly saving lives through screening,” Etta Pisano, the PI of the study led by ECOG-ACRIN Cancer Research Group, said to The Cancer Letter. “The question is, are we further reducing breast cancer mortality the more intensively we screen?”

Read The Cancer Letter article

NCORP Tissue Procurement Protocol to Open at 12 Community Sites

At 12 NCI Community Oncology Research Program (NCORP) sites across the United States, a new kind of study will soon be opening for patients with advanced malignancies being treated with molecularly targeted therapies. The NCORP Tissue Procurement Protocol (NCI 10231, NCT 03707574) is not a treatment trial, but a study to assess if researchers can obtain tissue and blood samples at baseline and upon progression in patients with advanced cancer being treated with molecularly targeted therapies.

Read the NCI DCP News Note

PREVENT Cancer Preclinical Drug Development Program (PREVENT)

PREVENT supports development of the best ideas in cancer prevention intervention and biomarkers using NCI contract resources instead of direct funding. The program is a peer-reviewed pipeline that focuses on research needs that are not adequately addressed by the private sector.

Read more About PREVENT